Last edition
News about "Pharmaceutical collaboration"
Roche and Nurix Partner to Develop BTK Degrader Bexobrutideg
Roche and Nurix Therapeutics have partnered to develop and commercialise bexobrutideg, a potential best-in-class BTK degrader for B-cell malignancies, chronic spontaneous urticaria, and Multiple Sclerosis (MS), aiming to overcome resistance to current BTK inhibitors.
Pharmaceutical Collaboration | 09/06/2026 | By News Bureau
OneSource-Backed Generic Semaglutide Secures Health Canada Approval
Orbicular and OneSource Specialty Pharma achieve a major milestone with Canada’s second generic Ozempic approval, strengthening their position in global peptide-based injectable markets.
Pharmaceutical Collaboration | 04/05/2026 | By News Bureau | 109
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy